GT19630

GT19630 is a first-in-class, small-molecule dual MYC/GSPT1 protein degrader being developed as a molecular glue for the treatment of MYC-driven cancers. As a cereblon E3 ligase modulator (CELMoD), it recruits the cereblon (CRBN) E3 ubiquitin ligase to induce the proteasome-mediated degradation of the MYC oncoprotein and G1 to S phase transition protein 1 (GSPT1). Preclinical studies have also demonstrated its ability to degrade the immune checkpoint protein B7-H3, suggesting potential immunomodulatory activity. Developed by Kintor Pharmaceutical, GT19630 has shown potent anti-cancer effects in various models, including acute myeloid leukemia (AML), multiple myeloma, small cell lung cancer (SCLC), and B-cell malignancies. The compound is currently in the IND-enabling stage.